AU2008315757A1 - Novel crystalline forms - Google Patents

Novel crystalline forms Download PDF

Info

Publication number
AU2008315757A1
AU2008315757A1 AU2008315757A AU2008315757A AU2008315757A1 AU 2008315757 A1 AU2008315757 A1 AU 2008315757A1 AU 2008315757 A AU2008315757 A AU 2008315757A AU 2008315757 A AU2008315757 A AU 2008315757A AU 2008315757 A1 AU2008315757 A1 AU 2008315757A1
Authority
AU
Australia
Prior art keywords
bosentan
crystalline form
process according
solid
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008315757A
Other languages
English (en)
Inventor
Prakash Bansode
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Sunanda Phadtare
Dattatraya Shinde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of AU2008315757A1 publication Critical patent/AU2008315757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008315757A 2007-10-24 2008-10-24 Novel crystalline forms Abandoned AU2008315757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2108/MUM/2007 2007-10-24
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (1)

Publication Number Publication Date
AU2008315757A1 true AU2008315757A1 (en) 2009-04-30

Family

ID=40262729

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008315757A Abandoned AU2008315757A1 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Country Status (8)

Country Link
US (1) US8530488B2 (enExample)
EP (1) EP2222649A2 (enExample)
JP (1) JP2011500780A (enExample)
CN (1) CN101939303B (enExample)
AU (1) AU2008315757A1 (enExample)
CA (1) CA2703230A1 (enExample)
NZ (2) NZ585438A (enExample)
WO (1) WO2009053748A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135795A2 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
AU2009203174B2 (en) * 2008-01-01 2014-01-30 Cipla Limited Method of synthesis of bosentan, its polymorphic forms and its salts
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
PT1254121E (pt) * 2000-01-25 2006-06-30 Hoffmann La Roche Preparacao de sulfonamidas
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) * 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
EP2222649A2 (en) 2010-09-01
CN101939303B (zh) 2014-06-11
WO2009053748A3 (en) 2009-06-18
NZ585438A (en) 2012-09-28
US8530488B2 (en) 2013-09-10
NZ600010A (en) 2013-11-29
US20100331352A1 (en) 2010-12-30
CN101939303A (zh) 2011-01-05
WO2009053748A2 (en) 2009-04-30
CA2703230A1 (en) 2009-04-30
JP2011500780A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
US8530488B2 (en) Crystalline forms of bosentan
AU2008247169B2 (en) Polymorphic forms of bosentan
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
US20110263649A1 (en) Crystalline form of lenalidomide and a process for its preparation
WO2020014406A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
US7994178B2 (en) Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
AU2008272685A1 (en) Process for introduction of hydroxyethoxy side chain in bosentan
US20240208889A1 (en) Solid state forms of tapinarof
US20040235904A1 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
US20060293377A1 (en) Amorphous and polymorphic forms of telmisartan sodium
EP4182318B1 (en) Solid state forms of rucaparib salts
US12534448B2 (en) Solid state form of lemborexant
CA3248508A1 (en) SOLID STATE FORMS OF MAVACAMTEN AND THEIR PREPARATION METHOD
WO2022177927A1 (en) Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
US20250066327A1 (en) Solid state forms of danicopan and process thereof
US20070043099A1 (en) Crystalline forms of carvedilol and processes for their preparation
US20220220149A1 (en) Solid state forms of sage-217 and processes for preparation thereof
AU2013200937A1 (en) Polymorphic forms of bosentan

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application